%0 Journal Article
%T Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study.
%A Vellek J
%A Tarawneh OH
%A Kazim SF
%A Owodunni OP
%A Arbuiso S
%A Shah S
%A Dicpinigaitis AJ
%A Schmidt MH
%A McKee RG
%A Miskimins R
%A Al-Mufti F
%A Bowers CA
%J World Neurosurg X
%V 23
%N 0
%D 2024 Jul
%M 38590738
暂无%R 10.1016/j.wnsx.2024.100367
%X •Intracranial hemorrhage accounts for two out of every three major intracranial hemorrhages.•Systemic anticoagulation is routinely prescribed for prevention of cerebrovascular accidents.•The FDA approved Andexanet alfa to treat life-threatening bleeding.•Andexanet alfa relationship to outcomes requires further investigation.